



**A NEET SS (SURGERY) PREPARATION COURSE
BY MARROW, WITH A TEAM OF SELECTED
SUPER-SPECIALITY FACULTY**

SURGERY NEET SS

oncology

**PREPARATION COURSE
BY MARROW, WITH A TEAM OF
SELECTED
SUPER-SPECIALITY FACULTY**

CONTENT

| | | |
|-----|---|-----|
| 1) | PRINCIPLES OF CANCER STAGING | 1 |
| 2) | ETIOLOGY OF CANCER 1 | 6 |
| 3) | ETIOLOGY OF CANCER 2 | 14 |
| 4) | ONCOGENIC VIRUSES 1 | 18 |
| 5) | ONCOGENIC VIRUSES 2 | 21 |
| 6) | CANCER SCREENING | 24 |
| 7) | RADIOTHERAPY IN ONCOLOGY 1 | 31 |
| 8) | RADIOTHERAPY IN ONCOLOGY 2 | 41 |
| 9) | TOBACCO USE & CANCER PATIENTS | 47 |
| 10) | ROLE OF SX. IN CANCER PREVENTION | 52 |
| 11) | RESPONSE EVA. CRITERIA IN SOLID TUM. | 61 |
| 12) | EMERGENCIES IN ONCOLOGY | 65 |
| 13) | SALIVARY GLAND TUMOR | 73 |
| 14) | OVERVIEW OF HEAD & NECK CANCERS | 82 |
| 15) | PRINCIPLES OF SX. IN MALIG. OF ORAL CA. | 99 |
| 16) | ORAL CAV. & OROPHARYN. CANCERS | 111 |
| 17) | HYPOPHAR.,NASAL & SINUS CANCERS | 126 |
| 18) | NECK DISSECTION | 134 |
| 19) | GUIDELINES - LARY. CANCER MGT. | 151 |
| 20) | GUIDELINES - OROPHY. CANCER MGT. | 158 |
| 21) | GUIDELINES - NASO. CANCER MGT. | 165 |
| 22) | NON SMALL CELL LUNG CANCER 1 | 170 |
| 23) | NON SMALL CELL LUNG CANCER 2 | 187 |
| 24) | NON SMALL CELL LUNG CANCER 3 | 201 |
| 25) | SMALL CELL LUNG CANCER | 211 |
| 26) | NET OF LUNG | 217 |
| 27) | MEDIASTINAL NEOPLASMA | 223 |
| 28) | MESOTHELIOMA | 236 |
| 29) | ESOPH. CANCER : INTRO. & EVALU. | 251 |
| 30) | ESOPHAGEAL CANCER : MANAGEMENT | 258 |
| 31) | GASTROESOPHAGEAL JUNCTION TUMORS | 264 |
| 32) | GASTRIC CANCER 1 | 271 |
| 33) | GASTRIC CANCER 2 | 277 |

| | | |
|-----|---------------------------------|-----|
| 34) | SMALL BOWEL TUMORS | 284 |
| 35) | COLON CANCER | 291 |
| 36) | COLON CANCER MGT. | 295 |
| 37) | MGT. OF POLYPS | 304 |
| 38) | RECTAL CANCER | 310 |
| 39) | CARCINOMA APPENDIX | 316 |
| 40) | HCC:CLINICAL FEAT. & EVALUATION | 321 |
| 41) | HCC:STAGING & MGT. | 329 |
| 42) | GALLBLADDER CANCER | 342 |
| 43) | BILE DUCT CANCER | 354 |
| 44) | PANCREATIC CANCER | 367 |
| 45) | GIST | 382 |
| 46) | GIST UPDATES | 394 |
| 47) | KIDNEY CANCER | 397 |
| 48) | BLADDER CANCER 1 | 403 |
| 49) | BLADDER CANCER 2 | 410 |
| 50) | PENILE CANCER | 415 |
| 51) | TESTICULAR CANCER 1 | 423 |
| 52) | TESTICULAR CANCER 2 | 428 |
| 53) | CERVICAL CANCER | 437 |
| 54) | CERVICAL INTRAPITHELIAL NEO. | 440 |
| 55) | CACINOMA ENDOMETRIUM | 452 |
| 56) | OVARIAN CANCER 1 | 461 |
| 57) | OVARIAN CANCER 2 | 468 |
| 58) | OVARIAN CANCER 3 | 479 |
| 59) | VAGINAL CARCINOMA VULVAR. | 490 |
| 60) | CARCINOM A | 494 |
| 61) | GTN | 500 |
| 62) | NET 1 | 506 |
| 63) | NET 2 | 510 |
| 64) | DIFFERENTIATED THYROID CANCER 1 | 519 |
| 65) | DIFFERENTIATED THYROID CANCER 2 | 530 |
| 66) | DIFFERENTIATED THYROID CANCER 3 | 541 |
| 67) | DIFFERENTIATED THYROID CANCER 4 | 556 |
| 68) | MEDULLARY THYROID CANCER | 564 |

| | | |
|-----|------------------------------------|-----|
| 69) | THYROID CARCINOMA : RT | 571 |
| 70) | PARATHYROID TUMORS | 577 |
| 71) | ADRENAL TUMORS | 583 |
| 72) | PHEOCHROMOCYTOMA | 592 |
| 73) | MEN SYNDROME 1 | 597 |
| 74) | MEN SYNDROME 2 | 607 |
| 75) | SKIN MALIGNANCY : INTRO. | 613 |
| 76) | MALIGNANT MELANOMA : MB | 619 |
| 77) | MALIGNANT MELANOMA : SBT & STAGING | 624 |
| 78) | MALIGNANT MELANOMA : EV. & MGT. | 635 |
| 79) | MALIGNANT MELANOMA : ADJ. THERAPY | 646 |
| 80) | MALIGNANT MELANOMA : UPDATES | 653 |
| 81) | BASAL CELL CARCINOMA 1 | 654 |
| 82) | BASAL CELL CARCINOMA 2 | 658 |
| 83) | SQUAMOUS CELL CARCINOMA | 661 |
| 84) | SKIN ADNEXAL TUMOR 1 | 667 |
| 85) | SKIN ADNEXAL TUMOR 2 | 675 |
| 86) | SKIN MALIGNANCY (IMAGE DISCUSSION) | 684 |
| 87) | BONE TUMORS 1 | 692 |
| 88) | BONE TUMORS 2 | 700 |
| 89) | SOFT TISSUE SARCOMAS 1 | 710 |
| 90) | SOFT TISSUE SARCOMAS 2 | 722 |
| 91) | BREAST 1 | 732 |
| 92) | BREAST 2 | 741 |
| 93) | BREAST 3 | 747 |
| 94) | BREAST 4 | 760 |
| 95) | CARCINOMA OF UNKOWN PRIMARY | 768 |

PRINCIPLES OF CANCER STAGING

Introduction

00:00:10

Purpose : To know the extent of the disease.

TNM Staging :

most widely used staging system.

Anatomical staging system.

3 components :

1. T category : Primary tumor.

- T x
 - T 0.
 - T is.
 - T 1.
 - T 2.
 - T 3.
 - T 4.
- } Invasive

2. N category : Regional lymph nodes (LN).

- N 0 : No nodes.
- N 1.
- N 2.
- N 3.

3. m category : Distant metastasis.

- m 0 : No distant metastasis.
- m 1 : Distant metastasis present.

Has sub-categories like a, b, c, d.

Evidence based system : upper stage → ↓ Survival.

Eg: Breast cancer :

T 1 : < 2 cm. T 2 : 2-5 cm. T 3 : > 5 cm.

1.8 cm and 1.9 cm tumors : No difference in survival.

1.9 cm and 2.1 cm tumors : Sharp difference in survival.

∴ Cut-off for upper stage is 2 cm.

| Group | Based on |
|------------------------------|--|
| cTNM | Clinical examination Radiological examination Surgical exploration without resection |
| pTNM | Pathology of resected tumor |
| yTNM : • ycTNM • ypTNM | Post-Neoadjuvant therapy (NACT) |
| rTNM : • rcTNM • rpTNM | Recurrence |
| aTNM | Autopsy (incidental detection) |

ycTNM : Clinical/radiological examination post-NACT.

ypTNM : Pathology of resected tumor post-NACT.

rcTNM : Clinical/radiological examination of recurrence.

rpTNM : Pathology of resected tumor of recurrence.

TNM Staging

00:09:40

T (Primary tumour) :

Tx : Cannot be assessed/Information not available.

Eg:

- Primary tumor operated elsewhere with no records.
- Extensive tumor where the primary cannot be identified.

T 0 : No primary tumor.

T is : In situ.

T 1-T 4 : Invasive.

N (Regional nodes) :

N x : Cannot be assessed.

N 0 : No nodes

N 1-N 3 : Nodes present.

m (distant metastasis) :

m 0 : No distant metastasis.

m 1 : Distant metastasis present.

No m x.

multiple tumors : Highest T mentioned.

Eg: Breast cancer :

- 3 tumors are present with largest being 6 cm.
- Staging : pT3 (m)/N 0/m 0 (or) pT 3 (3)/N 0/m 0 where (m) means multiple.
- Actual number of tumors can also be specified like (3).

Synchronous vs. metachronous :

- Cut-off of appearance of multiple tumors is 4 months from the diagnosis of primary.
- <4 months : Synchronous.
- >4 months : metachronous.
- metachronous malignancies are staged separately.
- Synchronous malignancies are staged together.
- Paired organs like lung included in the staging criteria.

Unknown primary :

- Evidence of nodal spread is present.
- Expected primary site does not show up.
- Categorized as T 0.
- Eg:
 - a. Axillary nodes present, no primary seen in breast.
 - b. Clinically → cT 0.
 - c. mastectomy is done and no primary is found → pT0.
 - d. Staging (as per suspected primary site) → Ca. Breast, T 0/N 1/m 0, Stage II.

Regional nodes :

Sentinel node :

- Represented as (sn).
- If only sentinel node biopsy is done then (sn) can be used.
- If complete dissection is done, then (sn) cannot be used.

FNAC proven nodes :

- Represented as (f).
- Eg: FNAC proven N1 : pN1 (f).


Isolated tumor cells :

- Cluster of < 200 cells.
- Size < 0.2 mm.
- Represented as (i+). Eg: pN1 (i+).
- It represents in-transit disease and not something that stations and proliferates.
- It is not considered as node +ve.
- Isolated cells are also considered node positive in aggressive malignancies :
 - a. melanoma.
 - b. merkel cell carcinoma.

Stage 0

00:20:13

In situ and non-invasive cancers.



Layers of GIT

Area below the serosa : Subserosa.

If serosa is absent, it is called **Adventitia**.

1. In situ : Not crossed a boundary to attain spread (no

spreading potential).

- Boundary can be :
 - a. Basement membrane : Oral cavity.
 - b. Muscularis mucosae : Colon.
- No potential to spread.
- Nodal / distant assessment not needed.

2. Complete Pathological response :

- Seen when tumor disappears after NACT.
- T 0/N 0/m 0.
- Not Stage 0 (stage 0 → in-situ).

3. Non-Invasive : Disease has not crossed basement membrane of epithelium.

- Very few cancers.
- Represented as T a.
- Eg : **Bladder cancer** : pT a/N 0/m 0.

4. DCIS :

- Can have nodal spread.
- Invasive component maybe missed on pathology.

ETIOLOGY OF CANCER I

Etiology & factors responsible for carcinogenesis

00:00:10

Rudolf Virchow proposed that lymphoreticular infiltrate in a tumor originates from chronic inflammation.

Types of inflammation :

| Tumor intrinsic | Tumor extrinsic |
|--|---|
| Cancer initiates and amplifies the inflammatory pathway → Promote survival, growth & invasion. | macroscopic environment of tumor contributes to carcinogenesis. |
| <p>E.g. :</p> <ul style="list-style-type: none"> Aflatoxin & aspergillus (↑ses mutagenesis) causing HCC. RET mutations → Non invasive follicular thyroid neoplasm → Promotes tumor development (promotion of inflammatory pathway) | <p>E.g. :</p> <ul style="list-style-type: none"> Chronic pancreatitis → Pancreatic carcinoma. H pylori → Stomach cancer. GERD → Esophageal ca. Hepatitis → HCC. |

Infections causing cancer :

| Cancer | Infection |
|--------------------|---|
| Bladder cancer | Schistosoma haematobium |
| Burkitt's lymphoma | EBV, HHPV 4 |
| Cervical cancer | HPV |
| Cholangiocarcinoma | Salmonella typhi, Opisthorchis viverrini, Clonorchis sinensis |
| Colorectal cancer | JC virus, Streptococcus bovis |
| Glioma | JC virus |

| | |
|------------------------------------|---|
| HCC | Hepatitis B, C, D, Schistosoma japonicum, Aflatoxin |
| Hodgkin's lymphoma | EBV |
| merkel cell cancer | merkel cell polyoma virus |
| mesothelioma | SV 40 |
| Adult T cell leukemia/ lymphoma | HTLV I |
| Prostate cancer | Xenotropic murine leukemia virus |
| Kaposi's sarcoma | HHV 8 |

Inflammatory mediators

00:08:48

The following have a role in interaction b/w tumor & host immune cells (cytokines):

- Chemokines.
- Interleukins : IL-1, IL-6, IL-8, IL-17.
- Interferons : I (α & β), II (γ), III (Δ_1 , Δ_2 & Δ_3).
- Prostaglandins.
- TNF α .

TNF : 1^o mediator of inflammation.

NF κ B pathway :

- major role in cancer.
- Activator of TNF.
- Initiation & transformation.

mechanism :

Inflammation \rightarrow Cytokines \rightarrow Promote release of inflammatory cells \rightarrow Oxidative damage, DNA mutation \rightarrow microenvironment in tissue is more conducive to increased cell growth, survival & transformation.

Survival of cell :

- Pro-inflammatory cytokines : IL-1 β , IL-8, TNF α & CRP
 \uparrow sed levels \rightarrow Reduced survival (poor prognosis).

- STAT 6 & STAT 3 ↑ expression (↑ inflammation) → inverse association of survival in mesothelioma.

Invasion :

- MMP 9 (matrix metalloproteinase 9) :
 - a. Gelatinase which degrades type IV collagen.
 - b. High expression shows poor prognosis (High chance of tumor invasion).
- HIFα : Increased vascular invasion in HCC → Poor prognosis.
- Cathepsin D : Increased association in inflammatory breast cancer.

Angiogenesis :

| Pro-angiogenic factors | Factors for angiogenesis |
|------------------------|-----------------------------------|
| TNFα | MIF : Endothelial cell activation |
| IL-1β | TGFβ (Head & neck SCC) |
| IL-8 | Angiopoietin-2 |

| Factors for metastasis |
|------------------------|
| VEGF |
| FGF 2 |
| PDGF |
| ICAM-1 |
| VCAM-1 |
| E-selectin |
| P-selectin |
| mmp-9 |

Molecular mechanism of carcinogenesis

00:18:00

1. NFκB pathway : Pro-tumorigenic.

mechanism :

- i. Chronic inflammation → EMT (epithelial mesenchymal transformation) activation → ↑ cell survival by promoting anti-apoptotic proteins → MYC & BCL-XL.

ii. Extracellular matrix remodeling by MMP & VEGF.

2. STAT 1 & 3 : Persistent STAT → Tumor inflammatory signal

+

NFKB



Tumor cell survival & angiogenesis

3. Inflammasome :

- Silica & asbestos can trigger inflammasome.
- Activates IL-1 β & IL-8 and other mediators (pro-inflammatory).

4. Toll like receptors (TLR) :

- Role in :
 - a. Host defense mechanism.
 - b. Tissue injury.
- Chronic inflammation → Chronic TLR pathway activation
→ Carcinogenesis.

Chemical factors

00:23:06

Scrotal cancer in chimney sweepers : First environmental cancer discovered by Percivall Pott.

| Cancer | Chemical carcinogens |
|-------------|---|
| Lung | Tobacco, asbestos, nickel. |
| Pleura | Asbestos. |
| Oral cavity | Tobacco, alcohol. |
| Esophagus | Tobacco, alcohol. |
| Gastric | Tobacco. |
| Colon | Tobacco, alcohol. |
| Liver | Aflatoxin, vinyl chloride, tobacco, alcohol. |
| Kidney | Tobacco, trichloroethylene. |
| Bladder | Tobacco, 4-amino biphenyl, 2-naphthylamine, cyclophosphamide, phenacetin. |
| Prostate | Cadmium. |

| | |
|------|--|
| Skin | Arsenic, coal tar, PAH, benzopyrenes, cyclosporin A. |
|------|--|

Chemical carcinogens



| Genotoxic | Non-genotoxic |
|---|---|
| Directly altering genetic material. | Independent of direct insult. |
| Damages DNA by : <ul style="list-style-type: none"> • DNA adducts. • Inducing DNA ssb (single stranded breaks) & dsb (double stranded breaks). | MAP (mitogen activated protein) kinase pathway (or) NFκB pathway They are epigenetic modifiers : <ul style="list-style-type: none"> • Cytotoxic. • Receptor mediated (steroid receptors & tamoxifen) |
| <ul style="list-style-type: none"> • Direct genotoxic : Cause cancer at site of exposure. Eg : UV induced skin cancer. • Indirect genotoxic : Require metabolic transformation from procarcinogen to carcinogen Eg : Aflatoxin. | |

Both can cause reactive oxygen species DNA damage alter gene expression.

Aristolochic acid :

- From genus of Aristolochia (plant).
- Used as herbal remedy for weight loss.
- Class I carcinogen.
- Causes A : T to T : A transversion.

- Diseases caused :
 - c. Balkan endemic nephropathy.
 - d. Nephrotoxic → Interstitial fibrosis.
 - e. upper tract urothelial carcinoma.

PAH (Polycyclic aromatic hydrocarbons) :

- ≥3 fused benzene rings.
- >200 chemicals.
- Benzopyrene : most studied PAH.
- metabolized by CYP4501A1 & CYP4503A4.
- mechanism of action : DNA adducts formation.
- Excretion : Glutathione pathway.
- ↑ risk lung & skin cancer.
- Found in overcooked food, coal burning and tobacco smoke.

IARC group I pharmaceutical carcinogens

00:35:13

| Drug | Cancer |
|---------------------|---|
| Azathioprine | Non-hodgkin's lymphoma, SCC of skin, HCC, cholangiocarcinoma. |
| Cyclophosphamide | Bladder cancer, leukemia. |
| Chlorambucil | Leukemia |
| Cyclosporine | Leukemia, lymphoma, non-melanomatous skin cancer. |
| Tamoxifen | Endometrial cancer |
| Estrogen /OCP /HRT. | Breast cancer, endometrial cancer. |

Physical factors :

- Ionising radiations : Ionize molecules (electron is displaced from orbit) by linear energy transfer (LET)
- Electromagnetic radiation : X rays & γ rays (have low LET).
- Particulate matter : Electron, proton, neutron, Carbon ion, α particles (have high LET).

m/c source of radiation exposure :

- 80% : Radon gas.
- 20% : medical sources.

Mechanism of action of ionising radiations

00:39:29

| Direct action | Indirect action |
|---|--|
| High LET : Direct DNA damage | Low LET |
| Direct energy transference to molecule. | Hydrolysis of H_2O releases \rightarrow OH^- radical \rightarrow DNA damage. |

Both causes similar lesions in DNA.

1 Gy of ionizing radiation :

- 40 dsb formed \rightarrow Critical lesions \rightarrow Cell lethality.
- 1000 ssb formed.
- 1000 single base lesions destroyed.
- 150 DNA protein crosslinks formed per cell.

Cell response to radiation :

1. Base excision repair : For ssb.
2. Homologous repair :
 - a. High fidelity repair (requires a contralateral DNA strand).
 - b. For dsb.
3. Non homologous end joining repair :
 - a. m/c mechanism of repair in ionising radiations.
 - b. For dsb.
 - c. Not accurate : Results in mutation.

Theoretical risk models for radiation induced cancer

00:43:46

1. Linear, no threshold model :

- most accepted.
- Induction of cancer is directly proportional to dose of radiation (even in low dose).

2. Sublinear / threshold model : Below threshold dose, risk is negligible.

3. Supralinear / Stealth model :

- Doses below threshold can trigger activation of DNA damage surveillance & repair mechanism → Sub-optimal activation of cell cycle.
- ↑ sed chance of mutation accumulation → Cancer.

4. Linear quadratic model : Radiation at low doses → Single tract of radiation hitting multiple targets → Quadratic induction rate.

Tissue vulnerable to radiation :

| vulnerability | Tissue / cells |
|-----------------|--|
| most vulnerable | Hematopoietic cell line (↑ all leukemia except CLL) > Thyroid gland. |
| Intermediate | Breast, lung, salivary gland. |
| Radioresistant | Skin, bone, GIT. |

ETIOLOGY OF CANCER II


Physical factors leading to carcinogenesis

00:00:08

UV light :

- UV A (320 to 400 nm) : mainly produces ROS → Single strand breaks & base lesions in DNA.
- UV B (290 to 320 nm).
- UV C (240 to 290 nm) : most damaging to DNA.
most of the UV C is absorbed by ozone layer.
- UV B & UV C : Forms pyrimidine dimers. And also 6 - 4 photoproducts that consists of covalent ring structures → Bending of DNA helix → Interfere in DNA synthesis.

Cellular reponse to UV radiation :



Asbestos :

- Contributes in causing 5 - 7 % of all lung cancers.
- mechanism of action : ROS → Single strand breaks + base lesions.
- Asbestos + tobacco : more chance of causing lung CA.
- Tumor suppressor genes p53 & p16INK4A + K-RAS oncogene are associated with lung CA caused by asbestos.

- **malignant mesothelioma** :
 - major cause : Asbestos fibres.
 - Associated with **PI6INK4A** & **NF2** gene mutation.

Radiofrequency radiation and microwave radiation :

- Radiofrequency radiation : 3 KHZ to 300 MHZ.
- microwave radiation : 300 MHZ to 300 GHZ.
- **Cellphones** :
 - Brain peak specific absorption rate : 4 to 8 w/kg.
 - > 10 yrs of cellphone usage : Increased chance of **glioma and acoustic neuroma**. It is **inconclusive** as large prospective studies have shown no risk.

Electromagnetic fields :

- **Not carcinogenic** (energy is not high enough to break chemical bonds).

Dietary factors

00:09:34

Dietary fibre :

- All plant polysaccharide & lignin → Resistant to hydrolysis by the digestive enzymes.
- **No association b/w dietary fibre and colorectal cancer.**

| | Increased incidence of | Decreased incidence of |
|------------------------------|--------------------------------------|---|
| Red meat | Colorectal CA | |
| Regular milk consumption | Prostate CA | Colorectal CA |
| Coffee | | HCC Endometrial CA Prostate CA |
| Vit D | | Colorectal CA Breast CA Prostate CA |
| Selenium (acc to SELECT RCT) | No protective effect in prostate CA. | |

mechanisms of redmeat being carcinogenic :

- ↑ Anabolic hormones in red meat.
- Polycyclic aromatic hydrocarbons (cooking at high temperature).
- ↑ Heme in red meat.
- Nitrates → Nitrosamines (in smoked, salted and processed meat).

Obesity and carcinogenesis

00:13:41

mechanisms of carcinogenesis in obese :

- Steroid hormone pathway.
- IGF pathway.

These 2 pathways are overactive in obese and lead to :

1. Increased endogenous estrogen → Increased incidence of breast and uterine CA.
2. Increased levels of insulin & C-peptides.
3. Increased levels of inflammatory mediators.

Physical activity :

Decreases the chances of cancer by following mechanisms.

- Increases immune surveillance.
- Decreases inflammation.
- Promotes insulin sensitivity.
- GF production & activation.
- Decreases obesity & central adiposity.
- Optimizes DNA repair capacity.
- Reduces oxidative stress.

Breast CA (in pre & post menopausal women) :

- Physical activity : Protective effect.
- Obesity : Increased incidence.

| Inadequate evidence to say that obesity has a role in following CA | Sufficient evidence to say that obesity has a role in following CA |
|---|---|
| Non cardia gastric CA. Extrahepatic biliary tract CA. Lung. melanoma. Testes. urinary bladder. Brain/ Spinal cord glioma. | Cardia gastric CA. Esophagus. Liver. Pancreas. Breast (post menopausal). Uterus. Ovary. Kidney. meningioma. Thyroid. |

Lack of physical activity & obesity is associated with poor outcomes in :

- Breast CA.
- Colorectal CA.
- Prostate CA.

ONCOGENIC VIRUSES I

Introduction

00:00:09

7 families of viruses, mainly seen in immunosuppressed patients.

most common : HPV.

HPV :

- Non enveloped DNA virus (alpha papilloma virus family).
- Causes cancer cervix, penile, anus, vagina ,vulva, tonsils, base of tongue and bladder.
- Infection rate > 70 %.

HBV & HCV :

| | | | |
|-----|-----------|---------------------------|--------------------------|
| HBV | DNA virus | Infection rate : 2 to 8 % | Hepatocellular carcinoma |
| HCV | RNA virus | Infection rate : < 3 % | |

Epstein Barr virus (EBV)/HHV 4 :

- DNA virus.
- Infection rate : 90 %.
- mainly found in B cell & pharyngeal mucosa.
- Causes Burkitt's, NHL, nasopharyngeal Ca.

Kaposi sarcoma Herpes virus (KSHV)/HHV 8 :

- DNA virus.
- Causes Kaposi sarcoma, multicentric castleman disease.

merkel cell polyoma virus :

- DNA virus.
- Causes merkel cell carcinoma.

Human T cell leukemia virus (HTLV) :

- RNA virus.

- Cause Adult T-cell leukemia, tropical spastic paraparesis.

BK polyoma virus :

- DNA virus.
- Cause bladder cancer.

Mechanism of viral oncogenesis

00:04:17

1. Direct mechanism :

- Virus infects cell → makes it malignant.
Viral oncogene expression → Direct genotoxin effect by viral gene products.
- Inactivation of p53/RB gene.

2. Indirect mechanism :

- **Cells are not infected.**
- Inflammatory response to virus → accelerated tissue damage & regeneration of non infected cells.

HPV :

- High risk : HPV 16, 18, 45, 31, 33, 52, 58, 35.
99 % : Cervical Ca.
HPV 16, 18 : 70 % of cases.
80 % : Anal canal Ca.
43 % : Vulval Ca.
70 % : Vaginal Ca.
- Increased incidence of head and neck Ca.
- **HPV association & cancer** : Nobel prize for medicine in 2008 → Harald zur Hausen.

Mechanism of action of HPV

00:08:20

1. Late phase proteins :

- L1, L2 (capsid proteins).
- Found in differentiating keratinocytes in skin & mucosa.
- HPV induced cancers are seen in the zone of

transition b/w stratified squamous & simple columnar.

- HrHPV : Lifetime risk > 70 %.
- a. Early phase proteins → (E1-E7) :
- E2 :
 1. Transcriptional repressor.
 2. E2 expression → Integrates viral episome into host DNA.
 3. Loss of E2 expression Increase upregulation of early gene expression.
 - E6 : p53 destruction & telomerase activation.
 - E7 : Interacts with RB → Blocks RB to trigger cell cycle arrest.

Epidermodysplasia verruciformis (EV) :

- Rare immunodeficiency.
- Numerous flat warty lesions containing beta papilloma virus will present → HPV 5/HPV 8.
- Develop squamous cell carcinoma in sun exposed areas.
- UV radiation is a cofactor.

HPV vaccines :

- Each vaccine contain L1 capsid protein of HPV 16, 18 → Organised into virus like particles → Given as vaccines.
- Immunogenic → High titre antibodies are produced against this.

Gardasil vaccine : HPV 6, 11, 16, 18.

Cervarix vaccine : HPV 16, 18.

ONCOGENIC VIRUSES II

Polyoma virus

00:00:09

Includes :

- BK/Human Polyoma Virus 1 : Kidney disease, bladder cancer.
- John Cunningham virus/Human Polyoma Virus 2 : Causes Progressive multifocal leukoencephalopathy (PMFL).

Both affects immunocompromised individuals.

merkel cell polyoma virus/Human Polyoma Virus 5 : 80% merkel's carcinoma, class 2A (probably carcinogen) carcinogens.

Affects patients with immunocompromised states like HIV, post organ transplants.

Ebstein Barr virus

00:02:30

History :

- Dennis Burkett noticed unusually B cell derived tumor involving jaw bones of children.
- Micheal Epstein and Yvonne Barr : Pathology of tumor.

Burkitt's tumor : EBV/HHV 4 (class 1 carcinogen).

EBV is also responsible for infectious mononucleosis and endemic burkitt's lymphoma (100 %).

Pathophysiology :

- Chronic infection of mature B cells.
- Patients with X-linked agammaglobulinemia are immune to this infection.

EBV associated malignancies :

Lymphoma (express CD20) :

- Burkitt's lymphoma : 20 % are sporadic (associated with EBV).
- Hodgkin's lymphoma.
- NK /T-cell lymphoma.

- Primary CNS lymphoma and Plasmablastic lymphoma.
- DLBCL.
- Post transplant lymphoproliferative disorder.

Carcinoma :

- 100 % association in nasopharyngeal carcinoma.
- 90 % of gastrolymphoepithelioma like carcinoma.

Kaposi sarcoma herpes virus/HHV 8 :

mainly seen in mediterranean region, eastern part of sub saharan Africa.

HIV/AIDS pandemic : Highly aggressive variants were seen.

Endemic region : 3rd m/c cancers in adults.

2 forms of B-cell proliferative disorders a/w HHV 8 :

1. Primary effusion lymphoma.
2. Multicentric castlemans disease.

Oncogenic retrovirus

00:11:13

ssRNA virus.

HTLV-I :

- Belongs to genus Delta.
- Only oncogenic retrovirus.
- Causes Adult T-cell leukemia/lymphoma :
Characterized by circulating tumor flower cells.
- Transmitted only via breastfeeding.

Hepatitis virus :

80 % HCC : HBV + HCV.

Developed countries : > 60% of HCC is by HCV.

Developing countries : 60% of HCC is by HBV.

Pathophysiology : Depress innate immunity.

Transmitted via body fluids, blood, semen (hepadna dsDNA virus).

Co-infection of HBV with HDV (ssRNA).

HBV vaccination reduces infection by > 70 %.

HCV :

Flaviviridae.

7 genotypes present.

Genotype 1 causes > 70 % infection.

Treatment : NSSB polymerase inhibitor (sofosbuvir), NS3-4A (telaprevir, boceprevir, simprevir).

Also causes B-cell NHL, DLBCL, marginal zone lymphoma and lymphoplasmacytic lymphoma.

Efficacy of antiviral therapy : Reduces chances of HCC by 50 %. Hence continuous surveillance is required.

Infectious carcinogens

00:18:35

1. Bacteria : H. pylori → Gastric adenocarcinoma, MALToma, gastric DLBCL.
2. Parasites :
 - Clonorchis sinenses
 - O. viverrini
 - S. hematobium : Bladder cancer.

H. pylori :

- Class I carcinogen.
- Non cardia gastric cancer, DLBCL and maltoma.
- Virulence factors : Cag A gene & VAC gene.
- Antibiotics & hygiene measures decreases infection.
- Eradication : Associated with increased risk of cardiac, gastric and esophageal cancers.

CANCER SCREENING

US preventive services task force (USPSTF)

00:00:12

| Grade | Definition | |
|-------|--------------------------------|---|
| A | USPSTF recommends the service | High certainty, that the net benefit is substantial. |
| B | Recommends | High certainty that the net benefit is moderate. |
| C | Recommends | moderate certainty that the net benefit is small. |
| D | Recommends against the service | moderate or high certainty that the service has no net benefit. |
| I | Insufficient evidence. | |

USPSTF guidelines for breast cancer

00:01:52

| USPSTF | ACS (American Cancer Society) |
|--|---|
| Against self breast examination (Recommendation D) | > 20 yrs : Self breast examination is an option. |
| Without mammography : >40 yrs : Insufficient evidence for clinical examination | Without mammography : 20 - 39 yrs : Clinical examination every 3 yrs. >40 yrs : Annual clinical examination |
| With mammography : 40 - 49 yrs : Individualized decision (Recommendation C). 50 - 74 yrs : Screen every 2 yrs (Recommendation B). >75 yrs : Insufficient evidence (Recommendation D). | With mammography : >40 yrs : Screen annually. |

Indication of MRI in screening :

- 20 % lifetime risk : MRI annually + mammography.
- 15 - 20 % lifetime risk : Can be discussed as an option.
- < 15 % lifetime risk : Do not screen with MRI.